SC 13D: Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities
Published on June 25, 2008
UNITED
      STATES
    SECURITIES
      AND EXCHANGE COMMISSION
    Washington,
      D.C. 20549
    SCHEDULE
      13D
    Under
      the Securities Exchange Act of 1934
    | 
               SICLONE
                INDUSTRIES, INC. 
             | 
          
| 
               (Name
                of Issuer) 
             | 
          
| 
               Common
                Stock, par value $.001 per share 
             | 
          
| 
               (Title
                of Class of Securities) 
             | 
          
| 
               825845209
                 
             | 
          
| 
               (CUSIP
                Number) 
             | 
          
| 
               Adrian
                Vazquez 
              1010
                N. Central Avenue, Suite 201, Glendale, CA
                91202 
             | 
          
| 
               (Name,
                Address and Telephone Number of Person Authorized to  
              Receive
                Notices and Communications) 
             | 
          
| 
               June
                13, 2008 
             | 
          
| 
               (Date
                of Event which Requires Filing of this
                Statement) 
             | 
          
If
      the filing person has previously filed a statement on Schedule 13G to report
      the
      acquisition that is the subject of this Schedule 13D, and is filing this
      schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the
      following box. o
    
Note:
      Schedules filed in paper format shall include a signed original and five copies
      of the schedule, including all exhibits. See § 240.13d-7 for other parties to
      whom copies are to be sent.
    *The
      remainder of this cover page shall be filled out for a reporting person’s
      initial filing on this form with respect to the subject class of securities,
      and
      for any subsequent amendment containing information which would alter
      disclosures provided in a prior cover page.
    The
      information required on the remainder of this cover page shall not be deemed
      to
      be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934
      (“Act”) or otherwise subject to the liabilities of that section of the Act but
      shall be subject to all other provisions of the Act (however, see the
      Notes).
Page 
          2
      SCHEDULE
      13D
    | 
               
CUSIP
                No.      825845209
 
             | 
          
| 
               1 
             | 
            
               NAMES
                OF REPORTING PERSONS 
              I.R.S.
                IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) 
              Adrian
                Vazquez 
             | 
          |||
| 
               2 
             | 
            
               CHECK
                THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) 
              (a)  o 
              (b)  o 
             | 
          |||
| 
               3 
             | 
            
               SEC
                USE ONLY 
               | 
          |||
| 
               4 
             | 
            
               SOURCE
                OF FUNDS (See Instructions) 
              OO 
             | 
          |||
| 
               5 
             | 
            
               CHECK
                IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS
                2(D) OR
                2(E) 
              o 
             | 
          |||
| 
               6 
             | 
            
               CITIZENSHIP
                OR PLACE OF ORGANIZATION 
              United
                States 
             | 
          |||
| 
               NUMBER
                OF 
              SHARES 
              BENE-FICIALLY 
              OWNED
                BY 
              EACH 
              REPORTING 
              PERSON 
              WITH 
             | 
            
               7 
             | 
            
               SOLE
                VOTING POWER 
              9,123,387 
             | 
          ||
| 
               8 
             | 
            
               SHARED
                VOTING POWER 
              0 
             | 
          |||
| 
               9 
             | 
            
               SOLE
                DISPOSITIVE POWER 
              9,123,387 
             | 
          |||
| 
               10 
             | 
            
               SHARED
                DISPOSITIVE POWER 
              0 
             | 
          |||
| 
               11 
             | 
            
               AGGREGATE
                AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 
              9,123,387 
             | 
          |||
| 
               12 
             | 
            
               CHECK
                BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See
                Instructions) 
              o 
             | 
          |||
| 
               13 
             | 
            
               PERCENT
                OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 
              
35.72%
                (Based on 25,540,420 shares of Common Stock issued and outstanding
                as of
                June 19, 2008) 
 
             | 
          |||
| 
               14 
             | 
            
               TYPE
                OF REPORTING PERSON (See Instructions) 
              IN 
             | 
          |||
Page 
            3
        
Item 1. Security
      and Issuer
    The
      title and class of equity securities to which this Schedule 13D relates is
      Common Stock, par value $.001 per share (the “Common Stock”), of Siclone
      Industries, Inc., a Delaware corporation (the “Issuer”). The address of the
      Issuer’s principal executive offices is 1010 N. Central Avenue, Suite 201,
      Glendale, CA 91202.   
    
Item 2. Identity
      and Background
    (a)
      This statement is being filed by Adrian Vazquez (the “Reporting Person”),
      individually.
    (b)
      The business address of the Reporting Person is c/o Siclone Industries, Inc.,
      1010 N. Central Avenue, Suite 201, Glendale, CA 91202
    (c)
      The Reporting Person’s present principal occupation is medical
      doctor.
    (d)
      The Reporting Person has not, during the last five years, been convicted in
      a
      criminal proceeding (excluding traffic violations or similar
      misdemeanours).
    (e)
      The Reporting Person has not, during the last five years, been a party to any
      civil proceeding of a judicial or administrative body of competent jurisdiction
      as a result of which he was or is subject to a judgment, decree or final order
      enjoining future violations of, or prohibiting or mandating activities subject
      to, federal or state securities laws or finding of any violation with respect
      to
      such laws.
    (f)
      The Reporting Person is a United States citizen.
    
Item 3. Source
      and Amount of Funds or Other Considerations
    Pursuant
      to an Agreement and Plan of Merger (the “Merger”) dated June 13, 2008 by and
      among the Issuer, Apollo Medical Management, Inc., and Apollo Medical
      Acquisition Co., Inc.,, the Issuer issued the Reporting Person 9,123,387 shares
      of the Issuer’s Common Stock of the Issuer in consideration for the capital
      stock of Apollo Medical Management, Inc., which were owned by the Reporting
      Person. After the Merger, the Reporting Person owned approximately 35.72% of
      the
      Issuer’s then outstanding shares of common stock. 
    
Item 4. Purpose
      of Transaction
    
The
      Reporting Person entered into the Merger to
      effect
      a change in control of the Issuer. 
    Since
      the
      date of the Merger, the Issuer’s principal focus has changed from seeking
      business opportunities to medical management.
    Except
      as described above, the Reporting Person has no definitive plan, arrangement
      or
      understanding to seek to cause the Issuer to be merged, reorganized or
      liquidated, to sell or transfer any assets of the Issuer, to cause the Issuer
      to
      change its current board of directors or management, to cause any material
      change to its capitalization, dividend policy, business, corporate structure,
      charter or bylaws, to cause the Common Stock to become eligible for termination
      of registration pursuant to Section 12(g)(4) of the Exchange Act, or to take
      any
      action similar to the above. 
    
Item 5. Interest
      in Securities of the Issuer
    
The
      Reporting Person beneficially owns 9,123,387 shares of Common Stock of the
      Issuer,
      which
      in aggregate represents 35.72% of the Issuer’s Common Stock based on
      25,540,420 shares
      of
      Common Stock issued and outstanding as of June 19, 2008.
      The
      Reporting Person has the sole power to vote or direct the vote, and to dispose
      or direct the disposition of such shares.
    Except
      as
      set out above, the Reporting Person has not effected any other transaction
      in
      any securities of the Issuer in the past sixty days.
    
Item 6. Contracts,
      Arrangements, Understandings or Relationships with Respect to Securities of
      the
      Issuer
    Pursuant
      to an Agreement and Plan of Merger (the “Merger”) dated June 13, 2008 by and
      among the Issuer, Apollo Medical Management, Inc., and Apollo Medical
      Acquisition Co., Inc.,, the Issuer issued the Reporting Person 9,123,387 shares
      of the Issuer’s Common Stock of the Issuer in consideration for the capital
      stock of Apollo Medical Management, Inc., which were owned by the Reporting
      Person. After the Merger, the Reporting Person owned approximately 35.72% of
      the
      Issuer’s then outstanding shares of common stock. 
    Page 
            4
        Item 7. Material to Be Filed as Exhibits
| Exhibit 99.1 | 
               Agreement
                and Plan of Merger dated June 13, 2008 by and among the Issuer, Apollo
                Medical Management, Inc., and Apollo Medical Acquisition Co., Inc.
                (Incorporated by reference to the Issuer’s Form 8-K filed with the
                Securities and Exchange Commission on June 19,
                2008) 
             | 
          
SIGNATURE
    After
      reasonable inquiry and to the best of my knowledge and belief, I certify that
      the information set forth in this statement is true, complete and
      correct.
    Dated:  
      June 24, 2008
    /s/
      Adrian Vazquez
    Adrian
      Vazquez